Tirzepatide-generic and compounded analogues

The pharmacology is not the issue; tirzepatide is a well-characterised dual agonist that produced roughly 20-22% weight loss in SURMOUNT-1. The issue is everything upstream of the receptor. Grey-market vials are labelled by nominal peptide content but frequently contain 60-95% of the stated mass, or occasionally more, and the balance is often mannitol, residual TFA salt and synthesis-related impurities including deletion sequences and diastereomers. Independent testing programmes have repeatedly found vials whose contents did not match the label, some containing a different incretin entirely. Compounded semaglutide products have been documented using salt forms — semaglutide sodium and semaglutide acetate — that are not the approved active ingredient and have no efficacy or safety data at all. On top of that sit sterility failures, endotoxin contamination and the dosing-error problem: the FDA and poison control centres have documented hospitalisations from users who confused units on an insulin syringe with milligrams or millilitres and injected ten to twenty times the intended dose. In a small but real number of cases the outcome has been severe hypoglycaemia, protracted vomiting and hospital admission.

Targets: GIP receptor, GLP-1 receptor

• · Start 2.5 mg weekly for 4 weeks, then 5 mg for 4 weeks, then increase by 2.5 mg every 4 weeks as tolerated to a maximum of 15 mg weekly. This is the approved schedule and there is no good reason to deviate from it. Anyone starting above 2.5 mg is trading tolerability for nothing.
• · Example: a 30 mg vial reconstituted with 3 mL of bacteriostatic water gives 10 mg/mL, so 2.5 mg is 0.25 mL — which on a U-100 insulin syringe is 25 units. Write the concentration on the vial. The overwhelming majority of reported grey-market incretin overdoses come from confusing units with milligrams or mixing up two vials at different concentrations.

Work out your exact syringe units →

• very commonNausea, vomiting, diarrhoea and constipation— Dose-dependent and worst in the two weeks after each escalation.
• commonExcessive lean mass loss— Unmanaged rapid weight loss on incretins runs 25-40% lean tissue. Protein intake and resistance training are not optional.
• uncommonAccidental overdose from unit confusion— Specific to self-reconstituted vials. Documented cases of ten- to twenty-fold overdoses causing protracted vomiting, dehydration and hospitalisation.
• uncommonInjection-site infection or abscess— Non-sterile compounding and poor technique; a real and underreported risk with grey-market vials.
• uncommonGastroparesis and severe delayed gastric emptying— Can persist after discontinuation and is a specific anaesthesia risk — tell any anaesthetist you are on an incretin.
• rarePancreatitis— Severe persistent abdominal pain radiating to the back means stop immediately and get imaging and a lipase.

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome - boxed warning on the approved product.
• History of pancreatitis.
• Pregnancy or attempting conception - discontinue at least 2 months before a planned pregnancy.
• Type 1 diabetes.
• Any vial with no certificate of analysis, no batch number and no independent third-party test result.

• cautioninsulin analogues — Serious hypoglycaemia risk; insulin and sulfonylurea doses generally need reducing before starting.
• cautionoral contraceptives — Delayed gastric emptying reduces absorption reliability; the tirzepatide label advises a backup method around initiation and each escalation.
• redundantretatrutide — Overlapping GLP-1 and GIP agonism; stacking two incretins multiplies GI toxicity without proportional benefit.
• synergycagrilintide — The amylin plus incretin combination is the basis of CagriSema and is genuinely additive, but the tolerability cost stacks too.

• · Weight and waist circumference every 2 weeks.
• · HbA1c and fasting glucose at baseline and every 3 months.
• · Lipase if persistent abdominal pain develops.
• · Body composition by DEXA if available, to catch excessive lean mass loss early.
• · Resting heart rate - incretins raise it modestly.

Tirzepatide is an FDA-approved prescription drug. Selling or supplying it outside the pharmacy chain is illegal in the US, EU and UK; the 'for research use only, not for human consumption' label is a legal fiction with no bearing on how the product is actually used. FDA compounding allowances that existed during the shortage period have been withdrawn now that tirzepatide and semaglutide are off the shortage list.

• Jastreboff et al. 2022, New England Journal of Medicine — SURMOUNT-1 tirzepatide for obesity (trial)
• FDA alerts on compounded semaglutide and tirzepatide dosing errors and non-approved salt forms (guideline)

Pharmacologically identical to tirzepatide - the same GIP/GLP-1 dual agonist - so nothing about mechanism, titration or expected effect differs. What differs is provenance: compounded and grey-market material is not manufactured under the same controls, and the relevant risks are identity, purity, concentration accuracy and sterility rather than pharmacology.

Dosing errors dominate, and they come from concentration rather than pharmacology. Compounded vials vary in mg/mL, and a person transferring a unit count from one vial to a differently concentrated one delivers the wrong dose - this has caused documented overdoses requiring hospital treatment. Salt forms such as tirzepatide sodium or acetate have also been sold; these are not the same substance as the studied molecule, and regulators have warned about them specifically.

• GIPR and GLP-1R — As tirzepatide

  As tirzepatide

As tirzepatide, when the material is what it claims to be.

Against branded tirzepatide the pharmacology is identical and the difference is entirely in supply-chain assurance. Third-party mass spectrometry per batch, with a batch number matching the vial, is the only thing that closes that gap.

• ?Content and purity vary between suppliers and between batches from the same supplier.
• ?The legal status of compounded GLP-1 and GIP agents has changed repeatedly and varies by jurisdiction.
• ?Salt-form products are chemically distinct from the studied molecule and have no supporting data.